39. Zhonghua Yi Xue Za Zhi. 2018 Mar 27;98(12):907-911. doi:10.3760/cma.j.issn.0376-2491.2018.12.006.[Analysis of neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) inHER-2-positive breast cancer].[Article in Chinese; Abstract available in Chinese from the publisher]Xu L(1), Ye JM, Zhu SN, Zhao JY, Xin L, Cheng YJ, Liu Q, Zhang H, Zhang S, DuanXN, Liu YH.Author information: (1)The Breast Disease Center of Peking University First Hospital, Beijing 100034,China.Objective: To analyze docetaxel (T) and carboplatin (C) combined with trastuzumab(H) -TCH regimen as neoadjuvant systemic therapy in early breast cancer patients with human epidermal growth factor receptor 2 (HER-2) positive. Methods: FromJanuary 2008 to December 2014, the data of patients diagnosed as early breastcancer in Breast Disease Center of Peking University First Hospital wereretrospective reviewed. The data of patients with HER-2 positive conducted TCHneoadjuvant therapy and surgery, and with the complete clinicopathologicalinformation were analyzed. Results: A total of 77 cases were enrolled in thisstudy. We defined G2+ G3+ G4+ G5 as responsive group according to Miller-Paynegrading system, the responsive rate was 84.4% (65/77). The rate of completepathological remission (pCR) was 39.0% (30/77). The 5-year disease free survival (DFS) was 87.3%, and 5-year overall survival (OS) was 93.6%. There was asignificant difference between DFS and OS in the responsive group andnon-responsive group (DFS: χ2=6.762, P=0.009; OS: χ2=5.062, P=0.024). Conclusion:TCH is an effective neoadjuvant therapy for patients with HER-2 positive breastcancer, and the toxic and side effects were under control.Publisher: 目的：探讨人类表皮生长因子受体2(HER－2)阳性早期乳腺癌患者采用多西他赛(docetaxel，T)、卡铂(carboplatin，C)联合曲妥珠单抗(trastuzumab，H)(TCH)方案新辅助治疗后的临床疗效。 方法：选择2008年1月至2014年12月北京大学第一医院乳腺疾病中心实施TCH新辅助化疗并接受手术的HER－2阳性早期乳腺癌患者进行回顾性研究，并结合术后病理疗效评价进行预后分析。 结果：共计77例临床病理资料及随访信息完整的患者进入本研究。其中，病理疗效评价有效率(G2＋G3＋G4＋G5)84.4%。病理完全缓解率(pCR)39.0%(30/77)。5年无病生存率(DFS)87.3%，5年总生存率(OS)93.6%，病理评价有效与无效患者的DFS与OS差异均有统计学意义(DFS：χ2＝6.762，P＝0.009；OS：χ2＝5.062，P＝0.024)。 结论： TCH方案是HER－2阳性乳腺癌患者有效的新辅助治疗方案，毒副反应可控。.PMID: 29665663 